Literature DB >> 25186441

Curcumin and dimethoxycurcumin induced epigenetic changes in leukemia cells.

Hazem E Hassan1, Samuel Carlson, Inas Abdallah, Thomm Buttolph, Karen C Glass, Tamer E Fandy.   

Abstract

PURPOSE: Curcumin is an ideal chemopreventive and antitumor agent characterized by poor bioavailability and low stability. The development of synthetic structural analogues like dimethoxycurcumin (DMC) could overcome these drawbacks. In this study we compared the cytotoxicity, metabolism and the epigenetic changes induced by both drugs in leukemia cells.
METHODS: Apoptosis and cell cycle analysis were analyzed by flow cytometry. Real-time PCR was used for gene expression analysis. DNA methylation was analyzed by DNA pyrosequencing. The metabolic stability was determined using human pooled liver microsomes. Chromatin Immunoprecipitation was used to quantify histone methylation.
RESULTS: Clinically relevant concentration of curcumin and DMC were not cytotoxic to leukemia cells and induced G2/M cell cycle arrest. DMC was more metabolically stable than curcumin. Curcumin and DMC were devoid of DNA hypomethylating activity. DMC induced the expression of promoter methylated genes without reversing DNA methylation and increased H3K36me3 mark near the promoter region of hypermethylated genes.
CONCLUSION: DMC is a more stable analogue of curcumin that can induce epigenetic changes not induced by curcumin. DMC induced the expression of promoter methylated genes. The combination of DMC with DNA methyltransferase inhibitors could harness their combined induced epigenetic changes for optimal re-expression of epigenetically silenced genes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25186441     DOI: 10.1007/s11095-014-1502-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  43 in total

1.  Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.

Authors:  X Yang; A T Ferguson; S J Nass; D L Phillips; K A Butash; S M Wang; J G Herman; N E Davidson
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

2.  Curcumin causes promoter hypomethylation and increased expression of FANCF gene in SiHa cell line.

Authors:  Gaurav Parashar; Nidarshana Chaturvedi Parashar; Neena Capalash
Journal:  Mol Cell Biochem       Date:  2012-06       Impact factor: 3.396

3.  Exploring pyrimidine-substituted curcumin analogues: design, synthesis and effects on EGFR signaling.

Authors:  Peiju Qiu; Lingling Xu; Lei Gao; Meng Zhang; Shixi Wang; Sheng Tong; Yue Sun; Lijuan Zhang; Tao Jiang
Journal:  Bioorg Med Chem       Date:  2013-07-02       Impact factor: 3.641

4.  Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation: H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3-methoxyphenyl groups.

Authors:  Wei-Feng Chen; Shui-Ling Deng; Bo Zhou; Li Yang; Zhong-Li Liu
Journal:  Free Radic Biol Med       Date:  2005-11-10       Impact factor: 7.376

5.  Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1).

Authors:  Rakesh K Srivastava; Qinghe Chen; Imtiaz Siddiqui; Krishna Sarva; Sharmila Shankar
Journal:  Cell Cycle       Date:  2007-12-01       Impact factor: 4.534

6.  Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells.

Authors:  Yan Chen; Wenxiu Shu; Weihua Chen; Qing Wu; Hongli Liu; Guohui Cui
Journal:  Basic Clin Pharmacol Toxicol       Date:  2007-10-09       Impact factor: 4.080

7.  Curcumin is a potent DNA hypomethylation agent.

Authors:  Zhongfa Liu; Zhiliang Xie; William Jones; Ryan E Pavlovicz; Shujun Liu; Jianhua Yu; Pui-kai Li; Jiayuh Lin; Jame R Fuchs; Guido Marcucci; Chenglong Li; Kenneth K Chan
Journal:  Bioorg Med Chem Lett       Date:  2008-12-14       Impact factor: 2.823

Review 8.  Current prospects of synthetic curcumin analogs and chalcone derivatives against mycobacterium tuberculosis.

Authors:  Syed Nasir Abbas Bukhari; Scott G Franzblau; Ibrahim Jantan; Malina Jasamai
Journal:  Med Chem       Date:  2013-11       Impact factor: 2.745

9.  Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

Authors:  Tamer E Fandy; James G Herman; Patrick Kerns; Anchalee Jiemjit; Elizabeth A Sugar; Si-Ho Choi; Allen S Yang; Timothy Aucott; Tianna Dauses; Rosalie Odchimar-Reissig; Jonathan Licht; Melanie J McConnell; Chris Nasrallah; Marianne K H Kim; Weijia Zhang; Yezou Sun; Anthony Murgo; Igor Espinoza-Delgado; Katharine Oteiza; Ibitayo Owoeye; Lewis R Silverman; Steven D Gore; Hetty E Carraway
Journal:  Blood       Date:  2009-06-22       Impact factor: 22.113

10.  Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation.

Authors:  Kevin Pruitt; Rebekah L Zinn; Joyce E Ohm; Kelly M McGarvey; Sung-Hae L Kang; D Neil Watkins; James G Herman; Stephen B Baylin
Journal:  PLoS Genet       Date:  2006-03-31       Impact factor: 5.917

View more
  14 in total

Review 1.  CpG and Non-CpG Methylation in the Diet-Epigenetics-Neurodegeneration Connection.

Authors:  Andrea Fuso; Marco Lucarelli
Journal:  Curr Nutr Rep       Date:  2019-06

2.  The combination of dimethoxycurcumin with DNA methylation inhibitor enhances gene re-expression of promoter-methylated genes and antagonizes their cytotoxic effect.

Authors:  Hazem E Hassan; Jean-Arnaud Keita; Lawrence Narayan; Sean M Brady; Richard Frederick; Samuel Carlson; Karen C Glass; Senthil Natesan; Thomm Buttolph; Tamer E Fandy
Journal:  Epigenetics       Date:  2016-11-01       Impact factor: 4.528

3.  "Curcumin, the King of Spices": Epigenetic Regulatory Mechanisms in the Prevention of Cancer, Neurological, and Inflammatory Diseases.

Authors:  Sarandeep S S Boyanapalli; Ah-Ng. Tony Kong
Journal:  Curr Pharmacol Rep       Date:  2015-01-30

Review 4.  Functional Foods: An Approach to Modulate Molecular Mechanisms of Alzheimer's Disease.

Authors:  Anna Atlante; Giuseppina Amadoro; Antonella Bobba; Valentina Latina
Journal:  Cells       Date:  2020-10-23       Impact factor: 6.600

5.  BMI1 is downregulated by the natural compound curcumin, but not by bisdemethoxycurcumin and dimethoxycurcumin.

Authors:  Temitope A Adeyeni; Natasha Khatwani; KayKay San; Uthayashanker R Ezekiel
Journal:  Physiol Rep       Date:  2016-08

6.  In vitro additive antitumor effects of dimethoxycurcumin and 5-fluorouracil in colon cancer cells.

Authors:  Huiying Zhao; Qingchun Liu; Saisai Wang; Fang Dai; Xiaofei Cheng; Xiaobin Cheng; Wenbin Chen; Min Zhang; Dong Chen
Journal:  Cancer Med       Date:  2017-06-02       Impact factor: 4.452

7.  Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.

Authors:  Hetty E Carraway; Sridhar A Malkaram; Yana Cen; Aymen Shatnawi; Jun Fan; Hamdy E A Ali; Zakaria Y Abd Elmageed; Thomm Buttolph; James Denvir; Donald A Primerano; Tamer E Fandy
Journal:  Sci Rep       Date:  2020-06-25       Impact factor: 4.379

Review 8.  A Promising Anticancer Agent Dimethoxycurcumin: Aspects of Pharmacokinetics, Efficacy, Mechanism, and Nanoformulation for Drug Delivery.

Authors:  Muhammad Sohail; Wenna Guo; Xin Yang; Zhiyong Li; Yanli Li; Hui Xu; Feng Zhao
Journal:  Front Pharmacol       Date:  2021-07-06       Impact factor: 5.810

Review 9.  Perspectives for synthetic curcumins in chemoprevention and treatment of cancer: An update with promising analogues.

Authors:  Adeoluwa Adeluola; Abu Hasanat Md Zulfiker; Daniel Brazeau; A R M Ruhul Amin
Journal:  Eur J Pharmacol       Date:  2021-06-17       Impact factor: 5.195

10.  Dimethoxy Curcumin Induces Apoptosis by Suppressing Survivin and Inhibits Invasion by Enhancing E-Cadherin in Colon Cancer Cells.

Authors:  Dong Chen; Fang Dai; Zhehang Chen; Saisai Wang; Xiaobin Cheng; Qinsong Sheng; Jianjiang Lin; Wenbin Chen
Journal:  Med Sci Monit       Date:  2016-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.